Research Management, Inc.

Austin, Texas 78758

1 studies enrolling now · 12 studies all time

What they study most

ADPKD, Alport Syndrome, Anemia, Anemia of Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney, CKD Associated With Type 1 Diabetes, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Chronic Kidney Diseases, Chronic Renal Failure, Chronic Renal Failure Requiring Hemodialysis, Diabetes Mellitus, Type 2

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX — Completed
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON — Stopped early
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) — Stopped early
• A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease — Completed
• KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) — Completed
• A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin — Completed
• A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy — Completed
• A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin — Completed
• A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis — Completed
• KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD — Completed
• Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa — Completed